Whether newer pacing techniques can mitigate death, LV decline, and HF symptoms in TAVI patients remains to be seen.

For every 100,000 runners who complete the full 42.2 km distance, there will be one cardiac arrest, new data show.

The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

AI outperformed clinicians and almost matched hs-TnT testing, but one expert questioned if this is where it’s needed most.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

While inconsistent dosing could have played a role, it still may be possible to identify the patients most likely to see ...

Additional research is needed to determine whether this is due to direct drug effects or underlying patient factors.